Royalty Pharma



Founded in 1996, Royalty Pharma focuses on the acquisition of pharmaceutical royalties, with over $16 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators ...

Jim Reddoch
EVP, Head of Research & Investments
Terrance Coyne
Chief Financial Officer
George Lloyd
EVP, Investments & General Counsel
Christopher Hite
EVP and Vice Chairman

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.